Recombinant human interleukin-2 (Beijing Four Rings Bio-Pharmaceutical)

重组人白介素-2(北京四环)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interleukin-2 (Beijing Four Rings Bio-Pharmaceutical)
Drug Alias Name德路生
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsCarcinoma, Renal CellMelanoma
Global Approved IndicationsCarcinoma, Renal CellMelanoma
Approved Indications in ChinaCarcinoma, Renal CellMelanoma
Original Approved Country/TerritoryMainland China
Original Approved Date1997/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsCarcinoma, Renal CellMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeL03AC01
Related LinksN/A